# Paul Shapiro

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 39 papers | 1,470 citations | 304743 22 h-index | 361022 35 g-index |
| 41 all docs | 41 docs citations | 41 times ranked | 2250 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib). Molecular Cancer Therapeutics, 2017, 16, 2351-2363. | 4.1 | 166 |
| 2 | Insulin-like Growth Factor-1 Regulates Endogenous RUNX2 Activity in Endothelial Cells through a Phosphatidylinositol 3-Kinase/ERK-dependent and Akt-independent Signaling Pathway. Journal of Biological Chemistry, 2004, 279, 42709-42718. | 3.4 | 139 |
| 3 | Identification of Novel Extracellular Signal-Regulated Kinase Docking Domain Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 4586-4595. | 6.4 | 112 |
| 4 | Cell Cycle-dependent Phosphorylation of the RUNX2 Transcription Factor by cdc2 Regulates Endothelial Cell Proliferation. Journal of Biological Chemistry, 2006, 281, 7118-7128. | 3.4 | 99 |
| 5 | Ras-MAP Kinase Signaling Pathways and Control of Cell Proliferation: Relevance to Cancer Therapy. Critical Reviews in Clinical Laboratory Sciences, 2002, 39, 285-330. | 6.1 | 93 |
| 6 | Tyrosine-Phosphorylated Extracellular Signalâ€“Regulated Kinase Associates with the Golgi Complex during G2/M Phase of the Cell Cycle. Journal of Cell Biology, 2001, 153, 1355-1368. | 5.2 | 67 |
| 7 | Smallâ€Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics. ChemMedChem, 2011, 6, 38-48. | 3.2 | 67 |
| 8 | Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 6281-6287. | 2.2 | 61 |
| 9 | Phosphorylation regulates nucleophosmin targeting to the centrosome during mitosis as detected by cross-reactive phosphorylation-specific MKK1/MKK2 antibodies. Biochemical Journal, 2004, 378, 857-865. | 3.7 | 52 |
| 10 | Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells. Journal of Biological Chemistry, 2017, 292, 13890-13901. | 3.4 | 47 |
| 11 | Requirement for phosphatidylinositol-3 kinase activity during progression through S-phase and entry into mitosis. Cellular Signalling, 2003, 15, 667-675. | 3.6 | 44 |
| 12 | Exosomal Proteome Profiling: A Potential Multi-Marker Cellular Phenotyping Tool to Characterize Hypoxia-Induced Radiation Resistance in Breast Cancer. Proteomes, 2013, 1, 87-108. | 3.5 | 44 |
| 13 | Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoprotein. European Journal of Medicinal Chemistry, 2016, 113, 273-292. | 5.5 | 42 |
| 14 | Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9. BMC Cancer, 2011, 11, 7. | 2.6 | 35 |
| 15 | Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf. Biochemical Journal, 2015, 467, 425-438. | 3.7 | 35 |
| 16 | Cdc2-mediated Inhibition of Epidermal Growth Factor Activation of the Extracellular Signal-regulated Kinase Pathway during Mitosis. Journal of Biological Chemistry, 2005, 280, 24524-24531. | 3.4 | 33 |
| 17 | Hyperglycemia Regulates RUNX2 Activation and Cellular Wound Healing through the Aldose Reductase Polyol Pathway. Journal of Biological Chemistry, 2009, 284, 17947-17955. | 3.4 | 32 |
| 18 | Novel Noncatalytic Substrate-Selective p38Î±-Specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-Inflammatory Activity. Journal of Immunology, 2017, 198, 3296-3306. | 0.8 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Development of Extracellular Signal-Regulated Kinase Inhibitors. Current Topics in Medicinal Chemistry, 2009, 9, 678-689. | 2.1 | 30 |
| 20 | Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling. Organic and Biomolecular Chemistry, 2013, 11, 3706. | 2.8 | 29 |
| 21 | Extracellular Signal-Regulated Kinase Positively Regulates the Oncogenic Activity of MCT-1 in Diffuse Large B-Cell Lymphoma. Cancer Research, 2009, 69, 7835-7843. | 0.9 | 28 |
| 22 | Effects of ATPâ€competitive and functionâ€selective ERK inhibitors on airway smooth muscle cell proliferation. FASEB Journal, 2019, 33, 10833-10843. | 0.5 | 25 |
| 23 | Use of Inhibitors in the Study of MAP Kinases. Methods in Molecular Biology, 2010, 661, 107-122. | 0.9 | 22 |
| 24 | Immunomodulatory Nanoparticles Mitigate Macrophage Inflammation via Inhibition of PAMP Interactions and Lactate-Mediated Functional Reprogramming of NF-Î°B and p38 MAPK. Pharmaceutics, 2021, 13, 1841. | 4.5 | 20 |
| 25 | Identification of a C-terminal Region That Regulates Mitogen-activated Protein Kinase Kinase-1 Cytoplasmic Localization and ERK Activation. Journal of Biological Chemistry, 2001, 276, 48494-48501. | 3.4 | 18 |
| 26 | Kinase inhibitors in the treatment of obstructive pulmonary diseases. Current Opinion in Pharmacology, 2020, 51, 11-18. | 3.5 | 16 |
| 27 | Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis. Oncotarget, 2020, 11, 3863-3885. | 1.8 | 13 |
| 28 | Targeting mitochondrial metabolism for metastatic cancer therapy. Molecular Carcinogenesis, 2022, 61, 827-838. | 2.7 | 13 |
| 29 | Protein Phosphatase 2A Activity Associated with Golgi Membranes during the G2/M Phase May Regulate Phosphorylation of ERK2. Journal of Biological Chemistry, 2005, 280, 11590-11598. | 3.4 | 11 |
| 30 | Using Caenorhabditis elegans as a model organism for evaluating extracellular signal-regulated kinase docking domain inhibitors. Journal of Cell Communication and Signaling, 2008, 2, 81-92. | 3.4 | 11 |
| 31 | A temperature-dependent conformational shift in p38Î± MAPK substrateâ€"binding region associated with changes in substrate phosphorylation profile. Journal of Biological Chemistry, 2019, 294, 12624-12637. | 3.4 | 9 |
| 32 | Avoiding or Co-Opting ATP Inhibition: Overview of Type III, IV, V, and VI Kinase Inhibitors. , 2020, , 29-59. | | 9 |
| 33 | Mechanistic Analysis of an Extracellular Signalâ€"Regulated Kinase 2â€"Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 84-97. | 2.5 | 5 |
| 34 | Discovering New MAP Kinase Inhibitors. Chemistry and Biology, 2006, 13, 807-809. | 6.0 | 3 |
| 35 | Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors. ACS Omega, 2022, 7, 3293-3311. | 3.5 | 3 |
| 36 | ERK2 Substrate Binding Domains Perform Opposing Roles in Pathogenesis of a JAK2V617F-Driven Myeloproliferative Neoplasm. Blood, 2021, 138, 2547-2547. | 1.4 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | A promiscuous kinase inhibitor reveals secrets to cancer cell survival. Journal of Biological Chemistry, 2019, 294, 8674-8675. | 3.4 | 0 |
| 38 | Comparisons of ATPâ€competitive (Type I) versus functionâ€selective (Type IV) ERK Inhibitors to Prevent Airway Smooth Muscle Cell Proliferation. FASEB Journal, 2019, 33, 793.2. | 0.5 | 0 |
| 39 | Developing Kinase Inhibitors Using Computer-Aided Drug Design Approaches. , 2020, , 81-108. | | 0 |